

CITATION REPORT

List of articles citing

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

DOI: 10.1007/s40273-017-0571-8

Pharmacoeconomics, 2018, 36, 131-144.

Source: <https://exaly.com/paper-pdf/69635251/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	CRTH2 antagonists in asthma: current perspectives. <i>Clinical Pharmacology: Advances and Applications</i> , 2017 , 9, 165-173	1.5	22
19	Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). <i>Respiratory Research</i> , 2018 , 19, 168	7.3	20
18	Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. <i>Pharmacoeconomics</i> , 2018 , 36, 957-971	4.4	48
17	The spectrum of therapeutic activity of mepolizumab. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 959-967	5.1	6
16	Responses to Biological Therapy in Severe Eosinophilic Asthma. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019 , 29, 335-337	2.3	
15	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019 , 74, 2087-2102	9.3	83
14	Resolution of inflammation: from basic concepts to clinical application. <i>Seminars in Immunopathology</i> , 2019 , 41, 627-631	12	11
13	Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. <i>Journal of Asthma</i> , 2020 , 1-11	1.9	2
12	Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden. <i>Journal of Medical Economics</i> , 2020 , 23, 877-884	2.4	4
11	Physical Activity: A Missing Link in Asthma Care. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	18
10	Real-world experience with mepolizumab: Does it deliver what it has promised?. <i>Clinical and Experimental Allergy</i> , 2020 , 50, 687-695	4.1	22
9	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021 , 14, 100509	5.2	5
8	Real-life cost-effectiveness of benralizumab in patients with severe asthma. <i>Respiratory Research</i> , 2021 , 22, 163	7.3	5
7	COVID vaccination and asthma exacerbation: might there be a link?. <i>International Journal of Infectious Diseases</i> , 2021 , 112, 243-246	10.5	4
6	2019 ARIA Care pathways for allergen immunotherapy. <i>Alergologia</i> , 2019 , 4, 134	0	3
5	Cost Utility of Bronchial Thermoplasty for Severe Asthma: Implications for Future Cost-Effectiveness Analyses Based on Phenotypic Heterogeneity. <i>ClinicoEconomics and Outcomes Research</i> , Volume 14, 427-437	1.7	
4	A pathogenic integrated view explaining the different endotypes of asthma and allergic disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> ,	9.3	0

- 3 Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype. **2022**, 10, 2635 1
- 2 Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy. **2022**, 12, 1692 0
- 1 Repurposing of Chemotherapeutics to Combat COVID-19. **2022**, 22, 2660-2694 1